Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure

Tariq Ahmad, Emily C. O'Brien, Phillip J. Schulte, Susanna R. Stevens, Mona Fiuzat, Dalane W. Kitzman, Kirkwood F. Adams, William E. Kraus, Ileana L. Pina, Mark P. Donahue, Faiez Zannad, David J. Whellan, Christopher M. O'Connor, G. Michael Felker

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background-Current heart failure (HF) risk prediction models do not consider how individual patient assessments occur in incremental steps; furthermore, each additional diagnostic evaluation may add cost, complexity, and potential morbidity. Methods and Results-Using a cohort of well-Treated ambulatory HF patients with reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, imaging, and exercise testing data, we estimated incremental prognostic information provided by 5 assessment categories, performing an additional analysis on those with available N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) levels. We compared the incremental value of each additional assessment (quality of life screen, laboratory testing, echocardiography, and exercise testing) to baseline clinical assessment for predicting clinical outcomes (all-cause mortality, all-cause mortality/hospitalization, and cardiovascular death/HF hospitalizations), gauging incremental improvements in prognostic ability with more information using area under the curve and reclassification improvement (net reclassification index), with and without NT-proBNP availability. Of 2331 participants, 1631 patients had complete clinical data; of these, 1023 had baseline NT-proBNP. For prediction of all-cause mortality, models with incremental assessments sans NT-proBNP showed improvements in C-indices (0.72 [clinical model alone]-0.77 [complete model]). Compared with baseline clinical assessment alone, net reclassification index improved from 0.035 (w/laboratory data) to 0.085 (complete model). These improvements were significantly attenuated for models in the subset with measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81 [full model]); net reclassification index improvements were similarly marginal (0.091→0.096); prediction of other clinical outcomes had similar findings. Conclusions-In chronic HF patients with reduced ejection fraction, the marginal benefit of complex prognostic evaluations should be weighed against potential patient discomfort and cost escalation. copy; 2015 American Heart Association, Inc.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalCirculation: Heart Failure
Volume8
Issue number4
DOIs
StatePublished - May 1 2015

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Mortality
Hospitalization
Quality of Life
Exercise
Costs and Cost Analysis
Area Under Curve
Echocardiography
Morbidity

Keywords

  • Brain
  • Echocardiography
  • Heart Failure
  • Hospitalization
  • Natriuretic Peptide
  • Quality Of Life

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ahmad, T., O'Brien, E. C., Schulte, P. J., Stevens, S. R., Fiuzat, M., Kitzman, D. W., ... Michael Felker, G. (2015). Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure. Circulation: Heart Failure, 8(4), 709-716. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001996

Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure. / Ahmad, Tariq; O'Brien, Emily C.; Schulte, Phillip J.; Stevens, Susanna R.; Fiuzat, Mona; Kitzman, Dalane W.; Adams, Kirkwood F.; Kraus, William E.; Pina, Ileana L.; Donahue, Mark P.; Zannad, Faiez; Whellan, David J.; O'Connor, Christopher M.; Michael Felker, G.

In: Circulation: Heart Failure, Vol. 8, No. 4, 01.05.2015, p. 709-716.

Research output: Contribution to journalArticle

Ahmad, T, O'Brien, EC, Schulte, PJ, Stevens, SR, Fiuzat, M, Kitzman, DW, Adams, KF, Kraus, WE, Pina, IL, Donahue, MP, Zannad, F, Whellan, DJ, O'Connor, CM & Michael Felker, G 2015, 'Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure', Circulation: Heart Failure, vol. 8, no. 4, pp. 709-716. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001996
Ahmad, Tariq ; O'Brien, Emily C. ; Schulte, Phillip J. ; Stevens, Susanna R. ; Fiuzat, Mona ; Kitzman, Dalane W. ; Adams, Kirkwood F. ; Kraus, William E. ; Pina, Ileana L. ; Donahue, Mark P. ; Zannad, Faiez ; Whellan, David J. ; O'Connor, Christopher M. ; Michael Felker, G. / Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure. In: Circulation: Heart Failure. 2015 ; Vol. 8, No. 4. pp. 709-716.
@article{2b4b49157dc745ceb75d769b27285184,
title = "Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure",
abstract = "Background-Current heart failure (HF) risk prediction models do not consider how individual patient assessments occur in incremental steps; furthermore, each additional diagnostic evaluation may add cost, complexity, and potential morbidity. Methods and Results-Using a cohort of well-Treated ambulatory HF patients with reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, imaging, and exercise testing data, we estimated incremental prognostic information provided by 5 assessment categories, performing an additional analysis on those with available N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) levels. We compared the incremental value of each additional assessment (quality of life screen, laboratory testing, echocardiography, and exercise testing) to baseline clinical assessment for predicting clinical outcomes (all-cause mortality, all-cause mortality/hospitalization, and cardiovascular death/HF hospitalizations), gauging incremental improvements in prognostic ability with more information using area under the curve and reclassification improvement (net reclassification index), with and without NT-proBNP availability. Of 2331 participants, 1631 patients had complete clinical data; of these, 1023 had baseline NT-proBNP. For prediction of all-cause mortality, models with incremental assessments sans NT-proBNP showed improvements in C-indices (0.72 [clinical model alone]-0.77 [complete model]). Compared with baseline clinical assessment alone, net reclassification index improved from 0.035 (w/laboratory data) to 0.085 (complete model). These improvements were significantly attenuated for models in the subset with measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81 [full model]); net reclassification index improvements were similarly marginal (0.091→0.096); prediction of other clinical outcomes had similar findings. Conclusions-In chronic HF patients with reduced ejection fraction, the marginal benefit of complex prognostic evaluations should be weighed against potential patient discomfort and cost escalation. copy; 2015 American Heart Association, Inc.",
keywords = "Brain, Echocardiography, Heart Failure, Hospitalization, Natriuretic Peptide, Quality Of Life",
author = "Tariq Ahmad and O'Brien, {Emily C.} and Schulte, {Phillip J.} and Stevens, {Susanna R.} and Mona Fiuzat and Kitzman, {Dalane W.} and Adams, {Kirkwood F.} and Kraus, {William E.} and Pina, {Ileana L.} and Donahue, {Mark P.} and Faiez Zannad and Whellan, {David J.} and O'Connor, {Christopher M.} and {Michael Felker}, G.",
year = "2015",
month = "5",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.114.001996",
language = "English (US)",
volume = "8",
pages = "709--716",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure

AU - Ahmad, Tariq

AU - O'Brien, Emily C.

AU - Schulte, Phillip J.

AU - Stevens, Susanna R.

AU - Fiuzat, Mona

AU - Kitzman, Dalane W.

AU - Adams, Kirkwood F.

AU - Kraus, William E.

AU - Pina, Ileana L.

AU - Donahue, Mark P.

AU - Zannad, Faiez

AU - Whellan, David J.

AU - O'Connor, Christopher M.

AU - Michael Felker, G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background-Current heart failure (HF) risk prediction models do not consider how individual patient assessments occur in incremental steps; furthermore, each additional diagnostic evaluation may add cost, complexity, and potential morbidity. Methods and Results-Using a cohort of well-Treated ambulatory HF patients with reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, imaging, and exercise testing data, we estimated incremental prognostic information provided by 5 assessment categories, performing an additional analysis on those with available N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) levels. We compared the incremental value of each additional assessment (quality of life screen, laboratory testing, echocardiography, and exercise testing) to baseline clinical assessment for predicting clinical outcomes (all-cause mortality, all-cause mortality/hospitalization, and cardiovascular death/HF hospitalizations), gauging incremental improvements in prognostic ability with more information using area under the curve and reclassification improvement (net reclassification index), with and without NT-proBNP availability. Of 2331 participants, 1631 patients had complete clinical data; of these, 1023 had baseline NT-proBNP. For prediction of all-cause mortality, models with incremental assessments sans NT-proBNP showed improvements in C-indices (0.72 [clinical model alone]-0.77 [complete model]). Compared with baseline clinical assessment alone, net reclassification index improved from 0.035 (w/laboratory data) to 0.085 (complete model). These improvements were significantly attenuated for models in the subset with measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81 [full model]); net reclassification index improvements were similarly marginal (0.091→0.096); prediction of other clinical outcomes had similar findings. Conclusions-In chronic HF patients with reduced ejection fraction, the marginal benefit of complex prognostic evaluations should be weighed against potential patient discomfort and cost escalation. copy; 2015 American Heart Association, Inc.

AB - Background-Current heart failure (HF) risk prediction models do not consider how individual patient assessments occur in incremental steps; furthermore, each additional diagnostic evaluation may add cost, complexity, and potential morbidity. Methods and Results-Using a cohort of well-Treated ambulatory HF patients with reduced ejection fraction who had complete clinical, laboratory, health-related quality of life, imaging, and exercise testing data, we estimated incremental prognostic information provided by 5 assessment categories, performing an additional analysis on those with available N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) levels. We compared the incremental value of each additional assessment (quality of life screen, laboratory testing, echocardiography, and exercise testing) to baseline clinical assessment for predicting clinical outcomes (all-cause mortality, all-cause mortality/hospitalization, and cardiovascular death/HF hospitalizations), gauging incremental improvements in prognostic ability with more information using area under the curve and reclassification improvement (net reclassification index), with and without NT-proBNP availability. Of 2331 participants, 1631 patients had complete clinical data; of these, 1023 had baseline NT-proBNP. For prediction of all-cause mortality, models with incremental assessments sans NT-proBNP showed improvements in C-indices (0.72 [clinical model alone]-0.77 [complete model]). Compared with baseline clinical assessment alone, net reclassification index improved from 0.035 (w/laboratory data) to 0.085 (complete model). These improvements were significantly attenuated for models in the subset with measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81 [full model]); net reclassification index improvements were similarly marginal (0.091→0.096); prediction of other clinical outcomes had similar findings. Conclusions-In chronic HF patients with reduced ejection fraction, the marginal benefit of complex prognostic evaluations should be weighed against potential patient discomfort and cost escalation. copy; 2015 American Heart Association, Inc.

KW - Brain

KW - Echocardiography

KW - Heart Failure

KW - Hospitalization

KW - Natriuretic Peptide

KW - Quality Of Life

UR - http://www.scopus.com/inward/record.url?scp=84942887862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942887862&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.114.001996

DO - 10.1161/CIRCHEARTFAILURE.114.001996

M3 - Article

C2 - 26034004

AN - SCOPUS:84942887862

VL - 8

SP - 709

EP - 716

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 4

ER -